Nathalie Mason
Clinical Researcher
Data updated
Research Footprint
Nathalie Mason appears in 46 tracked papers (2018–2026), most studied alongside Psilocybin, LSD and Ayahuasca, across Healthy Volunteers, Depressive Disorders and Anxiety Disorders.
Most-cited paper: Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin (258 citations).
Frequent co-authors: Johannes Ramaekers, Kim Kuypers and Jan Reckweg.
Publication Landscape
How the 46 papers Blossom tracks for Nathalie Mason line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Nathalie Mason's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 46 of 46 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Nathalie Mason publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Nathalie Mason publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Dr. Nathalie Mason is a clinical researcher specialising in human experimental psychopharmacology and early-phase clinical trials of psychedelic compounds. Her work spans controlled laboratory studies in healthy volunteers and phase 1/2 clinical investigations in patients, with a particular focus on classical serotonergic psychedelics (psilocybin, LSD) and rapidly acting tryptamines (notably inhaled 5‑MeO‑DMT). She has been involved in placebo-controlled and dose-ranging studies that probe acute subjective effects, pain perception, immune changes, and safety/tolerability profiles, and in translational trials assessing a vapourised 5‑MeO‑DMT formulation (GH001) for treatment‑resistant depression.
Key Impact
Notable for experimental and early-phase clinical studies characterising the subjective, physiological and potential therapeutic effects of classical psychedelics and novel tryptamines in humans.
Collaboration Network
64 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Nathalie Mason's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Nathalie Mason is associated with.